Enfortumab Vedotin PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
The antibody binds Nectin-4 on tumour cells and is internalised. Intracellular cleavage releases monomethyl auristatin E (MMAE), a microtubule-disrupting agent that inhibits cell division and induces apoptosis.
Indications / reported uses
Treatment of adults with locally advanced or metastatic urothelial cancer in combination with pembrolizumab as first-line therapy under the current US product indication
Treatment of adults with locally advanced or metastatic urothelial cancer previously treated with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy, where applicable under the product label
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Enfortumab Vedotin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Enfortumab Vedotin Permitted Daily Exposure (PDE) report (the Enfortumab Vedotin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Enfortumab Vedotin Occupational Exposure Limit (OEL) report (the Enfortumab Vedotin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.